Ionis Pharmaceuticals' zilganersen granted Priority Review by US FDA for Alexander disease treatment.

Ionis Pharmaceuticals has received a Priority Review from the US FDA for its NDA for zilganersen, an antisense oligonucleotide therapy for Alexander disease. The action date was set for Sept. 22. The designation was granted based on positive results from the clinical trials.